Investigation of gene expression and serum levels of PIN1 and eNOS with high blood pressure in patients with Alzheimer disease

2017 ◽  
Vol 43 ◽  
pp. 77-81 ◽  
Author(s):  
Mina Azimi ◽  
Masoud Nikanfar ◽  
Fatemeh khakikhatibi ◽  
Reza Rahbarghazi ◽  
Seyed Manuchehr Nourazarian ◽  
...  
2002 ◽  
Vol 282 (2) ◽  
pp. R343-R350 ◽  
Author(s):  
Miodrag Dodic ◽  
Arianne Peers ◽  
Karen Moritz ◽  
Vicky Hantzis ◽  
E. Marelyn Wintour

Exposure of pregnant ewes to dexamethasone, for only 2 days (term ∼150 days) at 27 days of gestation ( group D), results in adult offspring with high blood pressure. In this study, hemorrhage stress has been used to see whether in these animals the responsiveness of the hypothalamo-pituitary-adrenal (HPA) axis is altered. In addition, we studied mineralocorticoid (MR) and glucocorticoid (GR) receptor gene expression in the hippocampus and GR gene expression in the hypothalamus using real-time PCR. Calculated areas under the adrenocorticotropin, arginine vasopressin, and cortisol plasma concentration curves in response to hemorrhage were similar between the control and group D. In addition, there was no significant difference in the expression of MR and GR in the hippocampus or GR in the hypothalamus between the control and group D. Taken together, it is unlikely that reset in the HPA axis plays a major role in this particular model of “programmed” hypertension.


Author(s):  
Carlos Menendez-Castro ◽  
Nada Cordasic ◽  
Fabian B. Fahlbusch ◽  
Arif B. Ekici ◽  
Philipp Kirchner ◽  
...  

Abstract In malignant hypertension, far more severe kidney injury occurs than in the “benign” form of the disease. The role of high blood pressure and the renin–angiotensin–aldosterone system is well recognized, but the pathogenesis of the renal injury of malignant hypertension (MH) remains incompletely understood. Using the rat model of two-kidney, one-clip renovascular hypertension in which some but not all animals develop MH, we performed a transcriptomic analysis of gene expression by RNA sequencing to identify transcriptional changes in the kidney cortex specific for MH. Differential gene expression was assessed in three groups: MH, non-malignant hypertension (NMH), and normotensive, sham-operated controls. To distinguish MH from NMH, we considered two factors: weight loss and typical renovascular lesions. Mean blood pressure measured intraarterially was elevated in MH (220 ± 6.5 mmHg) as well as in NMH (192 ± 6.4 mmHg), compared to controls (119 ± 1.7 mmHg, p < 0.05). Eight hundred eighty-six genes were exclusively regulated in MH only. Principal component analysis revealed a separated clustering of the three groups. The data pointed to an upregulation of many inflammatory mechanisms in MH including pathways which previously attracted relatively little attention in the setting of hypertensive kidney injury: Transcripts from all three complement activation pathways were upregulated in MH compared to NMH but not in NMH compared with controls; immunohistochemistry confirmed complement deposition in MH exclusively. The expression of chemokines attracting neutrophil granulocytes (CXCL6) and infiltration of myeloperoxidase-positive cells were increased only in MH rats. The data suggest that these pathways, especially complement deposition, may contribute to kidney injury under MH. Key messages The most severe hypertension-induced kidney injury occurs in malignant hypertension. In a rat model of malignant hypertension, we assessed transcriptional responses in the kidney exposed to high blood pressure. A broad stimulation of inflammatory mechanisms was observed, but a few specific pathways were activated only in the malignant form of the disease, notably activation of the complement cascades. Complement inhibitors may alleviate the thrombotic microangiopathy of malignant hypertension even in the absence of primary complement abnormalities.


2018 ◽  
Vol 8 (1) ◽  
pp. 101 ◽  
Author(s):  
Hamidreza Abdolsamadi ◽  
Mohammad vahedi ◽  
Farnaz Fariba ◽  
Alireza Soltanian ◽  
Meghdad Zakavati Avval ◽  
...  

Introduction: Vitamin D deficiency is a major public health problem. Low vitamin D levels associated with adverse health consequences such as musculoskeletal health, cognitive decline and progression of cancer and death. The lack of vitamin D associated with major risk factors for cardiovascular disease (CVD) includes hypertension is considered. The ability to assess the general health, disease and treatment outcomes through saliva as a non-invasive, inexpensive and simple method of interest is located. The aim of this study was a comparative study of salivary and serum levels of vitamin D3 in patients with a history of developing high blood pressure and a healthy person.Methods: This study was a case - control survey, in which 40 patients with high blood pressure were examined. The control group including 40 healthy subjects. Both groups were matched in terms of age and gender. After collecting samples of serum and saliva, the amount of vitamin D level samples were measured using ELISA method by electrochemiluminescence (ELC), and then analyzed the results using software SPSS 16 and statistical test including Chi Square Test, Independent-Samples, linear regression model, the Mann-Whitney Test and Spearman correlation coefficient.Results: There was no significant difference in the mean serum levels of vitamin D among patients and healthy subjects (p= 0.588). In addition, there was no significant difference in the mean salivary levels of vitamin D between patients and healthy subjects (p= 0.833). There was no significant relationship between salivary and serum level of vitamin D in healthy individuals (p= 0.095). As well as there was no significant correlation between salivary and serum level of vitamin D in patients (p= 0.5).Conclusions: This study showed that vitamin D is a measurable marker in saliva, but its analysis in saliva, may not be a reliable tool for determining the vitamin D levels.


2021 ◽  
Vol 27 ◽  
Author(s):  
Nicolás Roberto Robles ◽  
Francesco Fici ◽  
Julian Valladares ◽  
Guido Grassi

: The presence of hypertension among the population with human immunodeficiency virus (HIV) has become a new threat to the health and well-being of people living with this disease, in particular, among those who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient requires the assessment of individual cardiovascular risk and its consideration when designing the individualized target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral. Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.


Sign in / Sign up

Export Citation Format

Share Document